43 results about "Anaphylactic reactions" patented technology

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

A use of oleanolic acid-28-O-β-D-glucopyranoside in the preparation of an anti-colitis drug is provided. The oleanolic acid-28-O-β-D-glucopyranoside has significant anti-ulcerative-colitis activity compared with parent nucleus oleanolic acid and other analogues, and has equivalent efficacy compared with Mesalazine, a first-line drug for the clinical treatment of inflammatory bowel disease, and can also avoid salicylic acid anaphylaxis possibly caused by Mesalazine western medicine treatment, thereby achieving a good application prospect.

The utility model relates to the technical field of underpants, and discloses an underpants capable of reducing friction to a human body, which comprises an underpants body, a skin-fitting lining layer is arranged on the inner side of a waist opening and / or two leg openings on the underpants body, and the skin-fitting lining layer is connected with the underpants body through an elastic connecting point or an elastic connecting wire. After the underpants are worn, the positions of the skin-fitting lining layer and the underpants body are relatively fixed, and in the action traction process, when the underpants body and the skin-fitting lining layer move relatively, the elastic connecting points or the elastic connecting wires are stretched by a certain length to overcome the traction force, so that the skin-fitting lining layer and the skin of the human body are kept stable and do not move; friction of the underpants to the waist and legs of a human body is improved, and anaphylaxis caused by friction of people with sensitive skin is reduced or avoided. The utility model has the characteristics of simple structure, low cost, strong practicability and good use effect.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions.

The invention provides an anti-coagulation coating. The anti-coagulation coating comprises an anti-coagulation component and a cross-linking agent, the preparation method of the anti-coagulation coating comprises the following steps: plasma activation: carrying out surface activation treatment on the surface of the conduit by adopting plasma; preparing a surface anti-coagulation coating: firstly preparing an anti-coagulation solution, immersing the catheter in the anti-coagulation solution containing phosphorylcholine, placing the catheter at room temperature after dip-coating, then placing the catheter in a curing box for curing, and taking out the catheter after the catheter is cooled to the room temperature, so as to prepare the catheter with the anti-coagulation coating containing phosphorylcholine; according to the anticoagulant coating, complications such as thrombus and fibrin sheath are reduced, the safety of a product is improved, anaphylactic reaction caused by drugs and heparin is avoided, and a passive anticoagulation mode is adopted, so that the blood coagulation capacity of a patient cannot be reduced, and the risk that a wound cannot be healed can be effectively reduced.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The invention provides a linear or cyclic polypeptide and a derivative or analogue thereof, wherein the linear or cyclic polypeptide is used for mobilizing a stress-inducing protein (sestrin) from GATOR / mTOR to sMAC in a non-aging cell; the polypeptide comprises or consists of an amino acid sequence derived from a stress-inducing protein or a truncated sequence thereof. These polypeptides are useful in the treatment of conditions requiring immediate intervention, such as acute diseases, sepsis caused by pathogen infection, or anaphylaxis, such as allergic shock, as immunotherapeutic agents for the treatment of cancer, and for autoimmune diseases.

The present disclosure relates to systems and methods for detection of food allergy in a subject. In particular, the disclosure provides systems and methods for early detection of oral food challenge (OFC)-related anaphylaxis by measuring transepidermal water loss (TEWL).

The present application relates to the technical field of skin care products, and discloses a composition with the effect of soothing sensitive skin, which is composed of the following components in mass percentage: plant extract 10-12%, skin repair factor 2-3%, jasmine hydrolat 10%, humectant 6-7%, and the balance being water. The composition with the effect of soothing sensitive skin has significant soothing effect, which is close to the soothing effect of common hormone ointments on the market. The composition can significantly reduce inflammatory factors, has good anti-inflammatory effect, simultaneously repairs damaged skin, enhances the moisturizing function, and enhances the skin barrier through the moisturizing and repairing effect. The composition has the effect of resisting anaphylaxis by reducing the content of trypsin and inhibiting the allergic reaction of mast cells. Human patch test and fish embryo development toxicity test prove that the composition with the effect of soothing sensitive skin has no skin adverse reactions and no development toxicity, is mild, safe and non-irritating, and is suitable for preparing skin care products for adults and infants.

The invention discloses a glomus huanghuai CRN effect protein as well as a coding gene and application thereof, the glomus huanghuai CRN effect protein is CRN4, and the amino acid sequence of the glomus huanghuai CRN effect protein is shown as SEQ ID NO.2. The invention further discloses a preparation method of the glomus huanghuai CRN effect protein. According to the invention, a gene CRN4 which is derived from glomus huanghuai and can trigger a plant anaphylactic reaction (HR) is obtained through a large amount of screening. The protein comprises a conservative LXLFLAK structural domain, and is a typical CRN effect protein. HR reaction can be stimulated, plant immunity is triggered, plants are induced to generate disease-resistant reaction, and great significance is achieved for developing environment-friendly disease-resistant strategies.

The invention discloses a method for preparing low-sensitization protein peptide through microwave combined enzymolysis composite modification and application, and relates to the technical field of food processing. The treatment method comprises the following steps: preparing protein powder into a solution, adding tea polyphenol into the solution, and uniformly mixing to prepare a protein solution; carrying out microwave modification treatment on the protein solution; adding compound protease into the protein solution subjected to microwave treatment for enzymolysis and enzyme deactivation; and filtering the enzymolysis product, and drying the filtrate to obtain the low-sensitization protein peptide. According to the method, microwave and enzymolysis combined composite modification is adopted, so that the sensitization of protein can be reduced, the reaction time is shortened, and the method is simple in process, free of pollution and high in safety. In the enzymolysis process, active peptide substances which are easy to digest and absorb, can enhance immunity and delay senescence are synchronously generated, and tea polyphenol added in the formula can synergistically relieve anaphylactic reaction and play an anti-oxidation role, so that multi-element synergy of desensitization, function enhancement and flavor optimization is realized, and the added value and market application potential of the product are improved.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to application of a compound in preparation of an anti-allergic reaction medicine. The compound provided by the invention can effectively inhibit mast cell degranulation so as to inhibit generation of IgE-mediated I-type anaphylaxis, so that the compound is used as an anti-drug anaphylaxis preparation to provide more possible treatment schemes for clinical drug anaphylaxis treatment.

Compositions and methods for treating diseases and conditions mediated by the high affinity IgE receptor (FcεRI) are provided. Also provided are antisense oligomers for modulating splicing of mRNA encoding a MS4A6A protein, optionally in addition to antisense oligomers for modulating splicing of mRNA encoding the FcεRIβ protein, thereby down-regulating cell-surface expression of FcεRI, and uses of the antisense oligomers for inhibiting mast cell degranulation, cytokine release, migration, and proliferation; for inhibiting anaphylaxis reactions in individuals, for treating allergic conditions in individuals, for reducing the incidence of allergic reactions in individuals, for treating individuals at risk of developing anaphylactic reactions, and for treating mast cell-related diseases in individuals.

The present application relates to the technical field of orthopedic artificial joint design and manufacturing, in particular to an intervertebral disc prosthesis and a preparation method thereof. The first plate body of the intervertebral disc prosthesis is provided with a semispherical groove on the side away from the first fixing seat; the second plate body is provided with a connecting slot on the side away from the second fixing seat; the nucleus pulposus prosthesis comprises a semispherical convex surface and a base, the semispherical convex surface is movably connected with the semispherical groove, and the base is connected with the connecting slot; the surfaces of the first plate body and the second plate body are both provided with gradient trabeculae, and the surfaces of the semispherical groove and the semispherical convex surface in contact with each other are both metal ceramic interfaces formed by zirconium-niobium surface oxidation. The upper end plate of the intervertebral disc prosthesis can keep relative movement with the nucleus pulposus prosthesis, and the contact friction interface of the relative movement is a metal ceramic interface formed by zirconium-niobium surface oxidation, so that the friction surface can reduce abrasion to the greatest extent, the wear resistance of the prosthesis is improved, the service life of the prosthesis is prolonged, the loosening of the prosthesis is improved, the metal allergic reaction and metal artifacts are reduced.

The present invention relates to a method for producing 1B or 1D omega-5 gliadin-deleted wheat and wheat produced thereby, and, specifically, to a method for producing and selecting 1B or 1D omega-5 gliadin gene-deleted wheat by using radiation. The method for producing 1B or 1D omega-5 gliadin-deleted wheat, according to the present invention, enables the production of a radiation breeding-based non-GMO mutant wheat or wheat breeding parental line while retaining agronomic traits similar to those of a wild-type wheat variety, and thus wheat with reduced toxicity to wheat-dependent exercise-induced anaphylaxis (WDEIA) can be produced for use in the production of processed wheat foods and the like, or a parental line for breeding wheat varieties with reduced toxicity to WDEIA can be produced.

The utility model discloses moisture absorption and sweat releasing underwear, which relates to the field of underwear, and comprises an underwear body, edge covering strips and an elastic band, the edge covering strips are arranged at the neckline, the shoulder opening and the lower hem of the underwear body, the elastic band is arranged at the lower hem of the underwear body, the underwear body is formed by compounding a plurality of layers of structures, and the underwear body sequentially comprises a skin-friendly layer, a moisture guiding layer, a quick-dry layer and a breathable outer layer from inside to outside. Due to the natural antibacterial and skin-friendly characteristics of the bamboo fibers, the underwear is softer and more comfortable when making contact with the skin, skin irritation and anaphylaxis caused by improper materials are reduced, protrusions and friction points at the sewing positions of the underwear are greatly reduced in a fine needle close sewing mode, and the underwear is more comfortable to wear. The skin discomfort caused by improper sewing is avoided, the overall wearing comfort is improved, the garment body sequentially comprises the skin-friendly layer, the moisture guiding layer, the quick-drying layer and the breathable outer layer from inside to outside, each layer has a specific function, and efficient moisture absorption and sweat releasing are achieved through cooperation of the layers.

Relates to an application of an anti-TSLP antibody or an antigen-binding fragment thereof and a nucleic acid molecule encoding the antibody in preparation of drugs for preventing and / or treating asthma, allergic inflammation, anaphylaxis or autoimmune diseases, the antibody or the antigen-binding fragment thereof has high affinity to TSLP, can effectively bind to TSLP and block the proliferation effect of TSLP on Ba / F3-hTSLPR-hIL7R alpha cells, and can be used for preparing drugs for preventing and / or treating asthma, allergic inflammation, anaphylaxis or autoimmune diseases. And the TSLP is capable of blocking the activation of PBMC (peripheral blood mononuclear cells) and secreting cytokines.

The invention discloses application of eucommia polysaccharide obtained by an ultrasonic-assisted hot extraction method in preparation of a product for relieving food allergy. Specifically, the application of the eucommia polysaccharide in preparation of a medicine for relieving tissue inflammation caused by food allergy, the application of the eucommia polysaccharide in preparation of a medicine for relieving intestinal tract tissue damage caused by food allergy and the application of the eucommia polysaccharide in preparation of a medicine for relieving food allergy by adjusting the structure and function of intestinal flora. The eucommia polysaccharide obtained through extraction and purification is applied to an OVA-induced mouse allergy model, a control group, an OVA sensitization group and a polysaccharide intervention group are set, and allergy symptom scores, tissue pathological changes and intestinal flora changes are evaluated. Researches prove that the eucommia polysaccharide has the effect of relieving food allergy and can be applied to preparation of products for relieving food allergy. Therefore, the invention provides a scientific basis for comprehensive utilization of eucommia ulmoides leaf resources in relieving food anaphylaxis.

The present invention refers to the medical field. Particularly, it refers to Glycosaminoglycan, or pharmaceutical composition comprising thereof, for use in a method for the prevention and / or treatment of anaphylaxis.

An intelligent dosing platform system for emergency medication administration comprising intelligent injection devices with emergency protocol modules, time-based tracking systems, and AI-driven prompting systems. The system analyzes time-based administration protocols for emergency medications, monitors elapsed time since previous medication administrations, and generates next dose prompts based on protocol timing requirements and elapsed time data. A field coordination module transmits administration timing data between field emergency response teams and remote coordination systems. The system supports emergency response environments including cardiac emergencies, anaphylaxis, opioid overdose response, and military field operations. Multi-modal alert systems deliver dose prompts through audible alerts, visual electronic medical record prompts, and remote physician communications. The system prevents duplicate medication administration across emergency response teams through timing data sharing while accounting for time delays caused by patient movement and transport.

The invention provides a model for predicting the risk of allergic reaction of a Wilson disease patient during copper expelling treatment, and belongs to the crossing field of clinical medicine and biological information technology. The risk prediction model comprises: an input module receiving patient parameter indexes composed of a sodium dimercaptopropanesulfonate injection dosage, a severe adverse drug reaction, a drug allergy history, a neutrophil count, a lymphocyte count, a ratio of neutrophil to lymphocyte, a ratio of platelets to lymphocyte, a leukocyte count, a urine copper level and a platelet count; the processing module is connected with the input module and is used for calculating the score and prediction probability of the allergic reaction during copper expelling treatment based on the parameter indexes of the patient; and the output module is connected with the processing module, and outputs the allergic reaction risk probability obtained by the risk prediction model during the copper expelling treatment of the Wilson disease patient. The risk prediction model can be conveniently used for early recognition and risk prediction of anaphylaxis of a Wilson disease patient during copper expelling treatment.

A prosthetic heart valve is disclosed for use in the treatment of structural heart diseases wherein the prosthetic heart valve comprises an expandable frame formed from a rhenium-containing metal alloy. The novel geometry of the expandable frame, in combination with the frame formed partially or entirely from the rhenium-containing alloy, enables the formation of a frame that: a) has an open mesh geometry in the frame of the prosthetic heart valve, which can be used to reduce delivery system size, and a) has an open mesh geometry in the frame of the prosthetic heart valve, which can be used to reduce delivery system size; the present invention relates to a bioprosthetic valve, b) with high radial strength, c) with improved recovery of physiological EGA, d) with lower backlash, e) without perspective shortening, f) allowing proper placement of the bioprosthetic valve relative to the natural junction of the valve, h) with symmetric and cylindrical expansion of the prosthetic valve, thereby reducing the incidence of leaflet thrombosis and structural valve deterioration, and to a method for manufacturing the same. And i) prevent anaphylaxis and restenosis associated with the nickel content.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The invention discloses a real-time penicillin anaphylaxis simulation teaching system, and relates to the field of simulation teaching, and the system comprises a data obtaining module which is used for obtaining the multi-modal data of a learner; the preprocessing module is used for preprocessing the multi-modal data to generate interaction data; the anaphylaxis degree calculation module is used for calculating the severity of anaphylaxis according to the interaction data; the anaphylaxis grade calculation module is used for calculating the anaphylaxis grade according to the severity of the anaphylaxis; the analog simulation module is used for adjusting vital signs of a virtual patient according to the anaphylactic reaction level, and the vital signs comprise the heart rate, the blood pressure and the blood oxygen saturation degree; the operation feedback module is used for generating operation feedback of the learner according to the vital signs of the virtual patient and the interaction data of the learner; the method has the advantage that the emergency response capacity of medical staff to penicillin allergy is improved.

The invention discloses an in-vitro evaluation method for anaphylactoid and type I anaphylaxis reactions caused by polymer impurities in beta-lactam antibiotics. The in-vitro sensitization evaluation method of the beta-lactam antibiotics is established for the first time, the risk of anaphylactoid and type I anaphylaxis caused by polymers in the beta-lactam antibiotics can be evaluated at the same time, the method can replace a traditional animal experiment method, the medicine consumption is reduced, repeatability is good, the result is visual, the experiment period can be greatly shortened, and the method has good application prospects. And a new thought is provided for the research of evaluating whether the polymer impurities in the beta-lactam antibiotics cause allergy and anaphylactoid or not and the evaluation of the drug safety.

Provided herein are methods and compositions for treating food allergies, infections, autoimmune conditions, and other allergic conditions. Also provided are methods for treating an infectious, autoimmune, or allergic disease in a subject comprising administering a composition comprising bacterium Anaerostipes caccae to the subject. Further aspects relate to a method for treating a food allergy or for reducing an allergic response to an allergen or for treating or preventing an anaphylactic response in a subject comprising administering a composition comprising bacterium Anaerostipes caccae and a prebiotic to the subject.

The disclosure provides stable liquid non-aqueous epinephrine and epinephrine prodrug formulations, including non-aqueous liquid dipivefrin HCl formulations. The formulations are suitable for use as oral spray, oral film, liquid-filled capsules or buccal, lingual, or sublingual drop formulation. The oral spray, oral film and liquid-filled capsule can be placed on the tongue, under the tongue (sublingual) or in the buccal space. Preferably, the oral spray is a sublingual spray. The disclosure provides a method for systemic delivery of a therapeutically effective amount of epinephrine to a subject comprising orally administering a non-aqueous liquid formulation of an epinephrine prodrug, such as dipivefrin HCl to the subject. The disclosure also includes a method of treatment of a disease amenable to treatment by in vivo delivery of systemic epinephrine comprising administering the disclosed formulations. The disease can be a respiratory disorder, type I allergic reactions including anaphylaxis and urticaria, or the disease can be cancer or a microbial infection.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The disclosure provides stable liquid non-aqueous epinephrine and epinephrine prodrug formulations, including non-aqueous liquid dipivefrin HCl formulations. The formulations are suitable for use as oral spray, oral film, liquid-filled capsules or buccal, lingual, or sublingual drop formulation. The oral spray, oral film and liquid-filled capsule can be placed on the tongue, under the tongue (sublingual) or in the buccal space. Preferably, the oral spray is a sublingual spray. The disclosure provides a method for systemic delivery of a therapeutically effective amount of epinephrine to a subject comprising orally administering a non-aqueous liquid formulation of an epinephrine prodrug, such as dipivefrin HCl to the subject. The disclosure also includes a method of treatment of a disease amenable to treatment by in vivo delivery of systemic epinephrine comprising administering the disclosed formulations. The disease can be a respiratory disorder, type I allergic reactions including anaphylaxis and urticaria, or the disease can be cancer or a microbial infection.